Meeting
2014 ASCO Annual Meeting
COMMAND: A phase II randomized, double-blind, placebo-controlled, multicenter study of defactinib as maintenance therapy in subjects with malignant pleural mesothelioma that has not progressed on at least four cycles of pemetrexed/platinum therapy.
Authors
Dean Anthony Fennell
University of Leicester, Leicester, United Kingdom
Dean Anthony Fennell , Paul Baas , Hedy Lee Kindler , Lee M. Krug , Anna Nowak , Marjorie Zauderer , Richard J. Gralla , Mitchell Keegan , Joanna Horobin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Mesothelioma
Clinical Trial Registration Number
NCT01870609
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS7611)
DOI
10.1200/jco.2014.32.15_suppl.tps7611
Abstract #
TPS7611
Poster Bd #
217B
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
ORION: A Phase 2, randomized, multicenter, double-blind study to assess efficacy and safety of durvalumab+olaparib vs durvalumab alone as maintenance therapy in Stage IV non-small cell lung cancer (NSCLC).
First Author: Myung-Ju Ahn
Poster
2020 ASCO Virtual Scientific Program
A phase II randomized study of telaglenastat, a glutaminase (GLS) inhibitor, versus placebo, in combination with pembrolizumab (Pembro) and chemotherapy as first-line treatment for KEAP1/NRF2-mutated non-squamous metastatic non-small cell lung cancer (mNSCLC).
First Author: Ferdinandos Skoulidis
Poster
2014 ASCO Annual Meeting
A phase 2 study of defactinib (VS-6063), a cancer stem cell inhibitor that acts through inhibition of focal adhesion kinase (FAK), in patients with KRAS-mutant non-small cell lung cancer.
First Author: David E. Gerber
Poster
2013 ASCO Annual Meeting
Double-blind randomized phase II trial of carboplatin and pemetrexed with or without OGX-427 in patients with previously untreated stage IV non-squamous non-small-cell lung cancer (NSCLC): The Spruce Clinical Trial.
First Author: David R. Spigel